Table S1.
Baseline demographics and clinical characteristics in the matched cohorts
| D-ER cohort (n=479) | Control cohort (n=479) | P-value | Standardized difference | |
|---|---|---|---|---|
| Sex | ||||
| Female | 356 (74.32) | 352 (73.49) | 0.7685 | 2 |
| Age | ||||
| Mean (± SD) | 51.81 (±9.76) | 49.13 (±10.41) | <0.0001 | 27 |
| Median | 53.00 | 52.00 | <0.0001 | |
| Treating or prescribing physician specialty | ||||
| Neurologist | 210 (43.84) | 209 (43.63) | 0.9481 | 0 |
| All other specialties | 269 (56.16) | 270 (56.37) | 0 | |
| PCP | 151 (31.52) | 41 (8.56) | <0.0001 | 60 |
| Rehabilitation | 2 (0.42) | 11 (2.3) | −16 | |
| Others | 31 (6.47) | 121 (25.26) | −53 | |
| Missing/unknown | 85 (17.75) | 97 (20.25) | −6 | |
| Quan–Charlson comorbidity index | ||||
| Mean (± SD) | 0.58 (±1.14) | 0.62 (±1.1) | 0.6454 | −3 |
| MS symptoms | ||||
| Muscular weakness/spasticity | 75 (15.66) | 75 (15.66) | 1.0000 | 0 |
| Disturbances of skin sensation | 71 (14.82) | 69 (14.41) | 0.8549 | 1 |
| Visual disturbances (including optic neuritis) | 38 (7.93) | 34 (7.1) | 0.6240 | 3 |
| Dizziness/giddiness/vertiginous syndromes | 36 (7.52) | 41 (8.56) | 0.5524 | −4 |
| Migraine | 20 (4.18) | 29 (6.05) | 0.1869 | −9 |
| Preindex MS-associated DMTs | ||||
| Glatiramer acetate | 100 (20.88) | 114 (23.8) | 0.2775 | −7 |
| Interferon-β-1a | 122 (25.47) | 133 (27.77) | 0.4213 | −5 |
| Natalizumab | 61 (12.73) | 54 (11.27) | 0.4865 | 4 |
| Interferon-β-1b | 43 (8.98) | 41 (8.56) | 0.8193 | 1 |
Notes: P-values are from two-sample t-tests/Wilcoxon rank-sum tests (for continuous variables) and X2-tests or Fisher exact tests (for categorical variables). A P-value <0.05 was prespecified to indicate statistical significance. All values are n (%) unless stated otherwise.
Abbreviations: D-ER, dalfampridine extended release; DMTs, disease-modifying therapies; MS, multiple sclerosis; PCP, primary care physician, including family/general and internal medicine; SD, standard deviation.